抗雌激素治疗在双膦酸盐相关颌骨坏死发生中的潜在意义。
Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw.
作者信息
Vaszilko Mihaly, Kovacs Evelin, Restar Laszlo, Balla Bernadett, Cseplo Krisztina, Kosa Janos, Lakatos Peter
机构信息
Dept. of Oral and Maxillofacial Surgery, Semmelweis University, H-1085 Budapest, Hungary.
Dept. of Oral and Maxillofacial Surgery, Semmelweis University, H-1085 Budapest, Hungary.
出版信息
J Craniomaxillofac Surg. 2014 Dec;42(8):1932-6. doi: 10.1016/j.jcms.2014.08.002. Epub 2014 Aug 20.
OBJECTIVES
There are known risk factors and established treatment protocols for bisphosphonate-related osteonecrosis of the jaw (BRONJ), but it remains a difficult disease to treat, with the risk of relapses. This study investigates whether or not there is a relationship between antiestrogen therapy and BRONJ.
PATIENTS AND METHODS
In our prospective study, we followed up 93 patients with BRONJ who were seen at our clinic between 2006 and 2011.
RESULTS
We found that breast cancer patients had a significantly worse prognosis than patients with other underlying illnesses (p < 0.01), which might indicate the role of antiestrogen therapy (p < 0.001) as a causative factor.
CONCLUSION
The dominance of the female gender among BRONJ patients as well as our new findings related to antiestrogen therapy of breast cancer raise the possibility that estrogen deficiency might be a newly discovered risk factor for BRONJ.
目的
双膦酸盐相关颌骨坏死（BRONJ）存在已知的风险因素和既定的治疗方案，但它仍是一种难以治疗且有复发风险的疾病。本研究调查抗雌激素治疗与BRONJ之间是否存在关联。
患者与方法
在我们的前瞻性研究中，我们对2006年至2011年间在我们诊所就诊的93例BRONJ患者进行了随访。
结果
我们发现乳腺癌患者的预后明显比其他基础疾病患者差（p < 0.01），这可能表明抗雌激素治疗（p < 0.001）作为致病因素的作用。
结论
BRONJ患者中女性占主导地位以及我们关于乳腺癌抗雌激素治疗的新发现增加了雌激素缺乏可能是BRONJ新发现的风险因素的可能性。
Zotero 插件